We would love to hear your thoughts about our site and services, please take our survey here.
Like this part:
The funding will enable the Company to progress it's new-frontier gold exploration programme in Cameroon, as well as pursue other opportunities it is reviewing in Africa and Europe.
Touching $1320 and climbing, chart looks very bullish. 5 year high is $1385, so all shaping up very nicely. GLA.
Commercial discussions progressing well and new parties interested. in no rush, as they have cash, they will take their time to ensure they get the best return ! http://www.pharmaxis.com.au/assets/Documents/pdf/02019/ASX/2019-01-30-Quarterly-Shareholder-Update-December-2018.pdf
https://www.cnbc.com/2019/01/29/after-a-long-slump-this-could-be-golds-year-.html?__source=twitter%7Cmain Could be good timing for that update.
https://watermelonshares.wordpress.com/2018/10/10/oriole-resources-orr/
Moving in the right direction in build up to news.
https://mobile.twitter.com/OrioleResources/status/1085856012660142081
Synairgen’s LOXL2 fibrosis drugs ready for phase II trials
Share
10:53 17 Jan 2019
With the receipt of long-term toxicity results, Synairgen and Pharmaxis now have all the data they need to take to potential partners.
Synairgen plc (LON:SNG) shares soared on Thursday after the respiratory drugs specialist confirmed its two Lysyl Oxidase Like 2 (LOXL2) inhibitors are now ready to enter phase II trials.
Pharmaxis, Synairgen’s partner in the programme, has received the results from three-month toxicology studies, completing the data package needed to advance talks with potential partners.
Aussie-listed Pharmaxis has been in talks with some “large pharma companies” over the past year or so and has now delivered the completed scientific package to those potential suitors.
“The successful completion of the longer-term toxicology studies completes the data set,” said Synairgen chief executive Richard Marsden.
“Pharmaxis is now conducting a final series of scientific briefings to potential partners. In accordance with the amended collaboration agreement with Pharmaxis, Synairgen will receive circa 17% of any future net partnering proceeds from all fibrotic indications for the LOXL2 inhibitors.
“We are really pleased about this positive development and look forward to further updates from Pharmaxis.”
Chances of ‘material upfront payment substantially increased’
Data from phase I trials back in November showed that the inhibitor compounds had the potential to be “best-in-class” treatments for a range of diseases such as Non-alcoholic Steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
“These data complete the overall phase I data package enabling Pharmaxis to conduct a final series of scientific briefings with potential partners before licensing,” said finnCap analyst Mark Brewer in a note to clients.
“Given the significant interest in NASH from large pharma and the sizable licensing deals (both upfront and long-term ‘bio-dollars’) that have historically completed in this field, the probability of Synairgen receiving a material upfront payment has substantially increased.”
Synairgen shares surged 17.6% to 15.9p on Thursday.
https://www.proactiveinvestors.co.uk/companies/news/212781/synairgens-loxl2-fibrosis-drugs-ready-for-phase-ii-trials-212781.html
Contd Implications. The intention is to license the LOXL2 programme to pharma/biotech who, having already conducted extensive final due diligence were awaiting the 3‐ month toxicity studies on both compounds. Synairgen will receive c.17% of any future net partnering proceeds from all fibrotic indications for the LOXL2 inhibitors. Given that upfront payments for Phase II-ready assets have been as high as $400m, with a median of closer to $100m, the probability of Synairgen receiving a sizeable upfront milestone payment has substantially increased. Valuation. We leave our valuation unchanged at £57m (£41m relates to SNG001) which implies a target price of 54p. This will rise on successfully licensing LOXL-2./
Tox studies for LOXL2 in today .
All good to go for our 17% interest it seems.,,
http://www.pharmaxis.com.au/investor-centre/news/view/pharmaxis-announces-loxl2-inhibitor-program-is-phase-2-ready-following-completion-of-13-week-toxicity-studies
Both drug compounds were tested at a range of doses in two species over a 13-week period to establish the No Observed Adverse Effect Level (NOAEL). For both compounds doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses in all toxicity studies and therefore an adequate safety margin to start phase 2 studies of up to 3 months in length.
With the data package complete, Pharmaxis is now conducting a final series of scientific briefings to potential partners.
Pharmaxis CEO Gary Phillips said, “The results of the toxicity studies complete our scientific package of data for the LOXL2 program. We have provided the large pharma companies who have been closely monitoring our progress with the latest study results and are now in the process of supporting them to complete their scientific due diligence. We are keen to answer remaining scientific questions of potential partners, discuss their proposed clinical development strategies should they acquire or license the program and progress discussions concerning appropriate commercial terms.”
Big sell showing @ 10p but SP not budged, strange ??!
Great news indeed. Slight delay on the toxicity study but only a couple of months and it’s not something that they can control (3rd party). Best in Class performance, I like that part !! https://www.proactiveinvestors.com.au/companies/news/209233/pharmaxis-receives-positive-results-from-clinical-trial-of-treatment-for-fibrotic-diseases
What’s not to like, massive potential and strong fundamentals.
Two of the trades were mine but didn't see the one close to the bell.
Surprised a £2K buy would move the needle.
Strange that we got a tick up on the bell with no trades????
Gary Phillips is on the record as saying that there is extra interest from large Pharmaceutical companies in LOXL2 due to the excellent results attained during the recent trial. Hopefully news will land soon reference a licencing partner.
GLA
That was me and was certainly a buy !
I have been watching this one for a while, they have a very compelling story, so I took the plunge today.
I see a little blue today, which is always nice after buying in!
The research I have done suggests for the patient there is plenty more to come; with a limited free float this could move fast when it get some momentum.
Old article but numbers relate to when we had 2 million shares, we now have 5 million - using same calculation that's £85m.
There is still hope.......
https://www.proactiveinvestors.co.uk/companies/news/167653/is-premier-african-worth-buying-for-its-stake-in-circum-minerals-alone-167653.html
Not looking to shabby either, 150k up to 300k since 1st May.